SCHEMBL9019170

SCHEMBL9019170

OCCO[C@@H](CO)OCc1ccccc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC1A3 P43003 2/20 0.41
SLC1A2 P43004 2/20 0.41
SLC1A1 P43005 2/20 0.41
CYP1A2 P05177 2/20 0.41
CYP2C19 P33261 2/20 0.41
MEN1 O00255 1/20 0.41
CYP2D6 P10635 1/20 0.41
CYP2C9 P11712 1/20 0.41
KMT2A Q03164 1/20 0.41
TSHR P16473 3/20 0.40
ALDH1A1 P00352 3/20 0.39
RECQL P46063 1/20 0.39
TDP1 Q9NUW8 1/20 0.39
CYP4F2 P78329 1/20 0.38
CYP4A11 Q02928 1/20 0.38
LTA4H P09960 1/20 0.38
EPHX2 P34913 1/20 0.38
IDO1 P14902 1/20 0.38
RCE1 Q9Y256 1/20 0.37
AGXT P21549 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9019164 1.00 SLC1A3 (0.41) SLC1A3SLC1A2SLC1A1CYP1A2CYP2C19
SCHEMBL2644673 0.90 TSHR (0.48) SLC1A3SLC1A2SLC1A1CYP1A2CYP2C19
SCHEMBL6005456 0.81 SLC1A3 (0.41) SLC1A3SLC1A2SLC1A1CYP1A2CYP2C19
SCHEMBL5566637 0.79 RCE1 (0.51) SLC1A3SLC1A2SLC1A1CYP1A2CYP2C19
SCHEMBL12694282 0.79 TSHR (0.44) SLC1A3SLC1A2SLC1A1CYP1A2CYP2C19
SCHEMBL6574317 0.78 PPARG (0.42) SLC1A3SLC1A2SLC1A1CYP1A2CYP2C19
SCHEMBL6005459 0.78 TSHR (0.45) SLC1A3SLC1A2SLC1A1CYP1A2CYP2C19
SCHEMBL1412775 0.76 ALDH1A1 (0.50) CYP2D6ALDH1A1RECQLLTA4HLMNA
SCHEMBL4904318 0.74 TSHR (0.39) MEN1KMT2ATSHRALDH1A1
SCHEMBL15366358 0.74 TSHR (0.48) SLC1A3SLC1A2SLC1A1CYP1A2CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250312474-A1 ANTHRACYCLINS AND CONJUGATES THEREOF SYNAFFIX B.V. (NL) 2025-10-09 US disclosed
EP-4572798-A1 ANTHRACYCLINS AND CONJUGATES THEREOF Synaffix B.V. (NL) 2025-06-25 EP disclosed
WO-2024038065-A1 ANTHRACYCLINS AND CONJUGATES THEREOF SYNAFFIX B.V. (NL) 2024-02-22 WO disclosed
EP-0434960-B1 Chiral 1,5-diiodo-2-methoxy or benzyloxy intermediates PHARMACIA SPA (IT) 1996-09-18 EP disclosed
US-5304687-A 1-alkoxy-2,2*-diiodo-diethyl ether which reacts with doxorubicin to yield anthrocycline antibiotics FARMITALIA CARLO ERBA S.R.L. (IT) 1994-04-19 US disclosed
EP-0434960-A1 Chiral 1,5-diiodo-2-methoxy or benzyloxy intermediates PHARMACIA S.p.A. (IT) 1991-07-03 EP disclosed
WO-1991009046-A1 MORPHOLINYL DERIVATIVES OF DOXORUBICIN AND PROCESS FOR THEIR PREPARATION FARMITALIA CARLO ERBA S.R.L. (IT) 1991-06-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250312474-A1 ANTHRACYCLINS AND CONJUGATES THEREOF ANTXR2, NCL, DUT SLC1A3 3339/4885SLC1A2 2736/4885SLC1A1 3191/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.